Improving early breast cancer detection: Focus on methylation

Annals of Oncology

Volumn 22, Issue 1, 2011, Pages 24-29

  Suijkerbuijk, K P M ^a   van Diest, P J ^a   van der Wall, E ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Breast neoplasms; DNA methylation; Early detection of cancer; Nipple aspirate fluid; Plasma; Serum

Indexed keywords

APC PROTEIN; BRCA1 PROTEIN; BRCA2 PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYTOSINE; DEATH ASSOCIATED PROTEIN KINASE; GLUTATHIONE TRANSFERASE P1; GUANOSINE; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; TRANSCRIPTION FACTOR TWIST; UVOMORULIN;

ASPIRATION BIOPSY; BREAST CANCER; BREAST CARCINOGENESIS; CANCER DIAGNOSIS; CANCER SCREENING; CHROMATIN IMMUNOPRECIPITATION; CPG ISLAND; DNA METHYLATION; EARLY DIAGNOSIS; GENE EXPRESSION; HUMAN; MAMMOGRAPHY; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; NIPPLE ASPIRATION; NUCLEAR MAGNETIC RESONANCE IMAGING; POLYMERASE CHAIN REACTION; PRECIPITATION; PRIORITY JOURNAL; PROMOTER REGION; REVIEW;

EID: 78650348240     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq305     Document Type: Review

References (59)

1. Claus EB, Schildkraut JM, Thompson WD, Risch NJ. The genetic attributable risk of breast and ovarian cancer. Cancer 1996; 77(11): 2318-2324.
2. Brekelmans CTM, Seynaeve C, Bartels CCM et al. Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk. J Clin Oncol 2001; 19(4): 924-930.
3. Hoogerbrugge N, Kamm YJ, Bult P et al. The impact of a false-positive MRI on the choice for mastectomy in BRCA mutation carriers is limited. Ann Oncol 2008; 19(4): 655-659.
4. Komenaka IK, Ditkoff BA, Joseph KA et al. The development of interval breast malignancies in patients with BRCA mutations. Cancer 2004; 100(10): 2079-2083.
5. Bird A. DNA methylation patterns and epigenetic memory. Genes Dev 2002; 16(1): 6-21.
6. Takai D, Jones PA. Comprehensive analysis of CpG islands in human chromosomes 21 and 22. Proc Natl Acad Sci U S A 2002; 99(6): 3740-3745.
7. Baylin SB, Herman JG. DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet 2000; 16(4): 168-174.
8. Jones PA, Laird PW. Cancer epigenetics comes of age. Nat Genet 1999; 21(2): 163-167.
9. Ehrlich M. DNA methylation in cancer: too much, but also too little. Oncogene 2002; 21: 5400-5413.
10. McCabe MT, Brandes JC, Vertino PM. Cancer DNA methylation: molecular mechanisms and clinical implications. Clin Cancer Res 2009; 15(12): 3927-3937.
11. Dworkin AM, Huang THM, Toland AE. Epigenetic alterations in the breast: implications for breast cancer detection, prognosis and treatment. Semin Cancer Biol 2009; 19(3): 165-171.
12. Mulero-Navarro S, Esteller M. Epigenetic biomarkers for human cancer: the time is now. Crit Rev Oncol Hematol 2008; 68(1): 1-11.
13. Duffy MJ, Napieralski R, Martens JWM et al. Methylated genes as new cancer biomarkers. Eur J Cancer 2009; 45(3): 335-346.
14. Schuebel KE, Chen W, Cope L et al. Comparing the DNA hypermethylome with gene mutations in human colorectal cancer. PLoS Genet 2007 3(9): e157.
15. Ushijima T, Asada K. Aberrant DNA methylation in contrast with mutations. Cancer Sci 2010; 101(2): 300-305.
16. Costello JF, Fruhwald MC, Smiraglia DJ. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat Genet 2000; 24(2): 132-138.
17. Momparler RL. Cancer epigenetics. Oncogene 2003; 22(42): 6479-6483.
18. Novak P, Jensen TJ, Garbe JC et al. Stepwise DNA methylation changes are linked to escape from defined proliferation barriers and mammary epithelial cell immortalization. Cancer Res 2009; 69(12): 5251-5258.
19. Esteller M. Epigenetics in cancer. N Engl J Med 2008; 358(11): 1148-1159.
20. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007; 128(4): 683-692.
21. Yan PS, Venkataramu C, Ibrahim A et al. Mapping geographic zones of cancer risk with epigenetic biomarkers in normal breast tissue. Clin Cancer Res 2006; 12(22): 6626-6636.
22. Love SM, Barsky SH. Breast-duct endoscopy to study stages of cancerous breast disease. Lancet 1996; 348(9033): 997-999.
23. Hoque MO, Prencipe M, Poeta ML et al. Changes in CpG islands promoter methylation patterns during ductal breast carcinoma progression. Cancer Epidemiol Biomarkers Prev 2009; 18(10): 2694-2700.
24. Lewis CM, Cler LR, Bu DW et al. Promoter hypermethylation in benign breast epithelium in relation to predicted breast cancer risk. Clin Cancer Res 2005; 11(1): 166-172.
25. Pasquali L, Bedeir A, Ringquist S et al. Quantification of CpG island methylation in progressive breast lesions from normal to invasive carcinoma. Cancer Lett 2007; 257(1): 136-144.
26. Sidransky D. Nucleic acid-based methods for the detection of cancer. Science 1997; 278(5340): 1054-1059.
27. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003; 349(21): 2042-2054.
28. Laird PW. The power and the promise of DNA methylation markers. Nat Rev Cancer 2003; 3(4): 253-266.
29. Suijkerbuijk KPM, Pan X, van der Wall E, van Diest PJ, Vooijs M. Comparison of different promoter methylation assays in breast cancer. Cell Oncol in press.
30. Fackler MJ, McVeigh M, Mehrotra J et al. Quantitative multiplex methylation-specific PCR assay for the detection of promoter hypermethylation in multiple genes in breast cancer. Cancer Res 2004; 64(13): 4442-4452.
31. Robertson G, Hirst M, Bainbridge M et al. Genome-wide profiles of STAT1 DNA association using chromatin immunoprecipitation and massively parallel sequencing. Nat Methods 2007; 4(8): 651-657.
32. Suijkerbuijk KPM, van der Wall E, van Diest PJ. Oxytocin: bringing magic into nipple aspiration. Ann Oncol 2007; 18(10): 1743-1744.
33. Suijkerbuijk KP, van der Wall E, Meijrink H et al. Successful oxytocin-assisted nipple aspiration in women at increased risk for breast cancer. Fam Cancer 2010 May 5 [Epub ahead of print]. doi: 10.1007/s10689-010-9344-7.
34. Krassenstein R, Sauter E, Dulaimi E et al. Detection of breast cancer in nipple aspirate fluid by CpG island hypermethylation. Clin Cancer Res 2004; 10(1): 28-32.
35. Zhu W, Qin W, Hewett JE, Sauter ER. Quantitative evaluation of DNA hypermethylation in malignant and benign breast tissue and fluids. Int J Cancer 2010; 126(2): 474-482.
36. Evron E, Dooley WC, Umbricht CB et al. Detection of breast cancer cells in ductal lavage fluid by methylation-specific PCR. Lancet 2001; 357(9265): 1335-1336.
37. Fackler MJ, Malone K, Zhang Z et al. Quantitative multiplex methylation-specific PCR analysis doubles detection of tumor cells in breast ductal fluid. Clin Cancer Res 2006; 12(11): 3306-3310.
38. Euhus DM, Bu D, Ashfaq R et al. Atypia and DNA methylation in nipple duct lavage in relation to predicted breast cancer risk. Cancer Epidemiol Biomarkers Prev 2007; 16(9): 1812-1821.
39. Locke I, Kote-Jarai Z, Fackler MJ et al. Gene promoter hypermethylation in ductal lavage fluid from healthy BRCA gene mutation carriers and mutation-negative controls. Breast Cancer Res 2007; 9(1): R20.
40. Antill YC, Mitchell G, Johnson SA et al. Gene methylation in breast ductal fluid from BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev 2010; 19(1): 265-274.
41. Jeronimo C, Monteiro P, Henrique R et al. Quantitative hypermethylation of a small panel of genes augments the diagnostic accuracy in fine-needle aspirate washings of breast lesions. Breast Cancer Res Treat 2008; 109(1): 27-34.
42. Euhus DM, Bu D, Milchgrub S et al. DNA methylation in benign breast epithelium in relation to age and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2008; 17(5): 1051-1059.
43. Jahr S, Hentze H, Englisch S et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 2001; 61(4): 1659-1665.
44. Brooks J, Cairns P, Zeleniuch-Jacquotte A. Promoter methylation and the detection of breast cancer. Cancer Causes Control 2009; 20(9): 1539-1550.
45. Hoque MO, Feng Q, Toure P et al. Detection of aberrant methylation of four genes in plasma DNA for the detection of breast cancer. J Clin Oncol 2006; 24(26): 4262-4269.
46. Martinez-Galan J, Torres B, Del MR et al. Quantitative detection of methylated ESR1 and 14-3-3-sigma gene promoters in serum as candidate biomarkers for diagnosis of breast cancer and evaluation of treatment efficacy. Cancer Biol Ther 2008; 7(6): 958-965.
47. Hu XC, Wong IH, Chow LW. Tumor-derived aberrant methylation in plasma of invasive ductal breast cancer patients: clinical implications. Oncol Rep 2003; 10(6): 1811-1815.
48. Dulaimi E, Hillinck J, Ibanez de Caceres I et al. Tumor suppressor gene promoter hypermethylation in serum of breast cancer patients. Clin Cancer Res 2004; 10(18): 6189-6193.
49. Taback B, Giuliano AE, Lai R et al. Epigenetic analysis of body fluids and tumor tissues: application of a comprehensive molecular assessment for early-stage breast cancer patients. Ann N Y Acad Sci 2006; 1075: 211-221.
50. Shukla S, Mirza S, Sharma G et al. Detection of RASSF1A and RARbeta hypermethylation in serum DNA from breast cancer patients. Epigenetics 2006; 1(2): 88-93.
51. Mirza S, Sharma G, Prasad CP et al. Promoter hypermethylation of TMS1, BRCA1, ERalpha and PRB in serum and tumor DNA of invasive ductal breast carcinoma patients. Life Sci 2007; 81(4): 280-287.
52. Sharma G, Mirza S, Prasad CP et al. Promoter hypermethylation of p16INK4A, p14ARF, CyclinD2 and Slit2 in serum and tumor DNA from breast cancer patients. Life Sci 2007; 80(20): 1873-1881.
53. Jing F, Zhang J, Tao J et al. Hypermethylation of tumor suppressor genes BRCA1, p16 and 14-3-3sigma in serum of sporadic breast cancer patients. Onkologie 2007; 30(1-2): 14-19.
54. Tan SH, Ida H, Lau QC et al. Detection of promoter hypermethylation in serum samples of cancer patients by methylation-specific polymerase chain reaction for tumour suppressor genes including RUNX3. Oncol Rep 2007; 18(5): 1225-1230.
55. Van der Auwera I, Elst HJ, Van Laere SJ et al. The presence of circulating total DNA and methylated genes is associated with circulating tumour cells in blood from breast cancer patients. Br J Cancer 2009; 100(8): 1277-1286.
56. Mirza S, Sharma G, Parshad R et al. Clinical significance of stratifin, ERa and PR promoter methylation in tumor and serum DNA in Indian breast cancer patients. Clin Biochem 2010; 43(4-5): 380-386.
57. Silva JM, Dominguez G, Villanueva MJ et al. Aberrant DNA methylation of the p16INK4a gene in plasma DNA of breast cancer patients. Br J Cancer 1999; 80(8): 1262-1264.
58. Bae YK, Shim YR, Choi JH et al. Gene promoter hypermethylation in tumors and plasma of breast cancer patients. Cancer Res Treat 2005; 37(4): 233-240.
59. Papadopoulou E, Davilas E, Sotiriou V et al. Cell-free DNA and RNA in plasma as a new molecular marker for prostate and breast cancer. Ann N Y Acad Sci 2006; 1075: 235-243.